Featured Research

from universities, journals, and other organizations

Urine LAM-ELISA Poor At Diagnosing TB, Study Suggests

Date:
August 27, 2009
Source:
BioMed Central
Summary:
Urine LAM-ELISA does not appear to be useful as an independent diagnostic test for pulmonary tuberculosis. A trial of the new diagnostic found that it was only capable of identifying 50.7 percent of TB cases.

Urine LAM-ELISA does not appear to be useful as an independent diagnostic test for pulmonary tuberculosis (TB). A trial of the new diagnostic found that it was only capable of identifying 50.7% of TB cases.

Klaus Reither led a team of researchers from the Ludwig-Maximilians-University of Munich, Germany, the University College London, UK, and the NIMR-Mbeya Medical Research Programme, Tanzania, who tested LAM-ELISA in 291 Tanzanian patients suspected of having TB. He said, "Only 35 out of 69 pulmonary TB cases, confirmed by smear microscopy and/or solid culture and/or liquid culture, showed at least one positive LAM-ELISA result. This 50.7% sensitivity of the LAM-ELISA was disappointingly low. The specificity of 87.8 % also fell far short of expectations".

Novel approaches are urgently needed to improve TB diagnosis and control. The LAM-ELISA detects lipoarabinomannan (LAM), a mycobacterium-specific lipopolysaccharide component of the bacilli's cell wall. In active mycobacterial disease, LAM is released into the blood and passes the renal barrier without major changes – suggesting that its detection in urine should be a reliable diagnostic indicator. Urine can be easily obtained and its collection is often more culturally accepted than the collection of sputum or blood samples.

Although this particular test did not fulfill the requirements for a stand-alone diagnostic test for pulmonary tuberculosis, the researchers speculate that it may still be of some use, "In our opinion, further investigations are needed to elucidate if the LAM-ELISA, in this stage of development, is valuable as a supplemental tool for the diagnosis of HIV-associated TB. This seems particularly important, when taking into consideration that TB is one of the most important opportunistic infections of HIV patients and that the sensitivity of smear microscopy in immunocompromised patients is low".


Story Source:

The above story is based on materials provided by BioMed Central. Note: Materials may be edited for content and length.


Journal Reference:

  1. Klaus Reither, Elmar Saathoff, Jutta Jung, Lilian T Minja, Inge Kroidl, Eiman Saad, Jim F Huggett, Elias N Ntinginya, Lucas Maganga, Leonard Maboko and Michael Hoelscher. Low sensitivity of a urine LAM-ELISA in the diagnosis of pulmonary tuberculosis. BMC Infectious Diseases, (in press) [link]

Cite This Page:

BioMed Central. "Urine LAM-ELISA Poor At Diagnosing TB, Study Suggests." ScienceDaily. ScienceDaily, 27 August 2009. <www.sciencedaily.com/releases/2009/08/090827192332.htm>.
BioMed Central. (2009, August 27). Urine LAM-ELISA Poor At Diagnosing TB, Study Suggests. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2009/08/090827192332.htm
BioMed Central. "Urine LAM-ELISA Poor At Diagnosing TB, Study Suggests." ScienceDaily. www.sciencedaily.com/releases/2009/08/090827192332.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com
$23.6 Billion Awarded To Widow In Smoking Lawsuit

$23.6 Billion Awarded To Widow In Smoking Lawsuit

Newsy (July 20, 2014) Cynthia Robinson claims R.J. Reynolds Tobacco Company hid the health and addiction risks of its products, leading to the death of her husband in 1996. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins